surpass 3 tirzepatide and muscle composition changes in people with type 2 diabetes ( SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase trial Efficacy of tirzepatide in phase

For most patients, this side effect is mild to moderate in severity and tends to resolve within several weeks as the body adjusts to the medication

A crucial question for those taking semaglutide is what happens once they stop using it

Patients with gastrointestinal disorders such as Crohns disease, celiac disease, or those who have undergone gastrointestinal surgeries (including gastric bypass) often experience impaired B12 absorption

These lifestyle shifts do more than just maintain weight loss they enhance overall well-being

Low early complication rates after arthroscopic meniscus repair and meniscectomy

While the FDA has approved both Celexa and Lexapro to manage major depressive disorder (MDD), only Lexapro is registered for the treatment of generalized anxiety disorder (GAD)